RH
Therapeutic Areas
Protara Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TARA-002 | Non-Muscle Invasive Bladder Cancer (NMIBC), BCG-unresponsive Carcinoma In Situ (CIS) | Phase 2 |
| IV Choline Chloride | Intestinal Failure-Associated Liver Disease (IFALD) | Phase 2 |
Leadership Team at Protara Therapeutics
JS
Jesse Shefferman
Chief Executive Officer
JA
Julianne Averill
Chief Financial Officer & Chief Operating Officer
BR
Blaine Rath
Executive Vice President, General Counsel & Corporate Secretary
HC
Hannah Chism
Executive Vice President, Clinical Development